Efficacy of pharmacological and microbiota-based therapies in preclinical models of autism spectrum disorder: a systematic review.
Arnas Kunevičius, Kinga Gawlińska, Aurelijus Burokas et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review evaluated the efficacy of pharmacological and microbiota-based therapies in preclinical models of autism spectrum disorder (ASD). Analyzing 52 studies from 2010 to 2025, the review found that ASD-like behavioral deficits can be modulated through diverse interventions targeting neurotransmission, neuroinflammation, metabolism, and the gut-brain axis, highlighting the complexity of ASD pathophysiology.
Key findings
- 52 studies were reviewed, focusing on pharmacological and microbiota-based therapies for ASD.
- Interventions included oxytocinergic agents, metabolic drugs, cannabinoids, and microbiota-directed strategies.
- ASD-like behavioral deficits can be modulated through diverse biological system interventions.
- The findings suggest a need for a systemic approach to ASD treatment.
Why it matters
Understanding the multifactorial nature of ASD can guide clinicians in exploring a wider range of therapeutic options, moving beyond traditional narrowly targeted interventions to more comprehensive strategies that address various biological systems.